Andrew D.c. LaFrence, Chief Financial Officer at Vyant Bio, Inc. (VYNT), bought 3,000 shares at $3.28 ($10K) on 2021-05-20, disclosed to the SEC on 2021-05-21.
Open-market purchase of $10k VYNT by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.